TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05574764

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cultivating Awareness and Resilience in Education (CARE)
Description: CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cultivating Awareness and Resilience in Education (CARE)
Description: CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cultivating Awareness and Resilience in Education (CARE)
Description: CARE provides teachers and staff with tools and resources to reduce stress, prevent burnout, enliven teaching, and help students thrive socially, emotionally, and academically. CARE blends instruction with experiential activities, reflection, and discussion.
Study: NCT06290011

Intervention type: DEVICE
Intervention: Pain key group
Description: mixed real pain treatment software, pain treatment scenarios in MR
Study: NCT06145048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VGT-309
Description: Intravenous drug to be given over 15-20 minutes by syringe pump.
Study: NCT05030441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: . Patients should take ivosidenib at approximately the same time every day, with or without food, but should be instructed to avoid a high-fat meal as well as grapefruit and grapefruit products.
Study: NCT05811533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spencer's MET with conventional therapy
Description: Patients will be asked to lie in a side lying position with the affected shoulder above. The therapist will stabilize the shoulder girdle with the proximal hand and the distal hand provided force into the restrictive barrier of shoulder in 7 different movements. During all the movements, patients will ask to use their muscle energy 20% against the slight resistance offered by the therapist for 3-5 seconds. The patient then asks to relax and exhale after that shoulder joint will move beyond the barrier to achieve the next barrier. After 20 sec of rest, this technique will be repeated 3-5 times

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post-Facilitation Stretch with conventional therapy
Description: Muscle Energy Technique \[Post Facilitation Stretch)\] for the shoulder joint will be applied with 3 repetitions per set, 1 session per day. Patient will be instructed to perform a full strength contraction of the muscle to be stretch for 10 seconds. The muscle is then allow to fully relax, whereupon a rapid stretch of the affected muscle will be performed and will held in position by the physician for 15 sec. Patient will be asked to relax and whole cycle will be repeated
Study: NCT05920928

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Short course radiotherapy with concurrent capecitabine(825mg/m2)
Description: Compared to conventional treatments, short-term radiotherapy has lower fraction numbers but higher radiation doses per fraction. capecitabine is given during treatment time (825mg/m2)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Long course radiotherapy with concurrent capecitabine(825mg/m2)
Description: Long-term radiation is administered in conjunction with concomitant capecitabine (825mg/m2)
Study: NCT05715671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: The corresponding esketamine dose for each group was used at the end of anesthesia induction, and esketamine was changed to the corresponding maintenance dose for each group prior to surgical skin incision.
Study: NCT05805358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperpolarized 13C-Pyruvate injection
Description: DNP-MRI for splenic immune function evaluation through hyperpolarized 13C-Pyruvate injection
Study: NCT04870736

Intervention type: PROCEDURE
Intervention: Mout-to-mouth ventilation
Description: Chest rising during basic life support will be recorded as No breath (no visible chest rising) and Breath (chest rising) by the observer.

Intervention type: PROCEDURE
Intervention: Mout-to-mouth ventilation
Description: Chest rising during basic life support will be recorded as No breath (no visible chest rising) and Breath (chest rising) by the observer.

Intervention type: PROCEDURE
Intervention: Mout-to-mouth ventilation
Description: Chest rising during basic life support will be recorded as No breath (no visible chest rising) and Breath (chest rising) by the observer.

Intervention type: PROCEDURE
Intervention: Mout-to-mouth ventilation with quantitative analysis
Description: Chest rising during basic life support will be recorded and evaluated (breath by breath) in QCPR Skill Reporter software

Intervention type: PROCEDURE
Intervention: Mout-to-mouth ventilation with quantitative analysis
Description: Chest rising during basic life support will be recorded and evaluated (breath by breath) in QCPR Skill Reporter software
Study: NCT05610085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam Injection
Description: Neonates will be treated with intravenous levetiracetam 60mg/kg for first line management of seizures, and if seizures persist will be randomized to receive higher dose Levetiracetam or standard of care phenobarbital

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital Sodium Injection
Description: Standard of care for neonatal seizures
Study: NCT05871983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MUNICH TRANSCATHETER MITRAL VALVE REPLACEMENT SYSTEM
Description: The replacement valve consists of a self-expanding, tri-leaflet, dry bovine -pericardial valve. The dry tissue allows the valve to be conveniently pre-loaded. The key characteristics of Munich valve are:~* Nitinol stent frame~* Bovine pericardium~* Polyester skirt~* Anchoring system allows anchoring the frame to the annulus~* Hooks are used to reduce the mobility of the native leaflets and decrease risk of embolization.~The Munich TMVR system design proposed for this clinical investigation represents a significant evolution from previous TMVR designs:~* Transfemoral / transseptal access~* Self-expanding~* Dry pericardium (can be pre-loaded)~* No anchors~* 27 Fr delivery catheter (~* Sizes: 40/48/55mm~* Height 30 mm The valve is available in 3 sizes with a 30mm profile and has been designed to reduce the complexity of implantation in comparison to other TMVR systems.
Study: NCT04698265

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human amniotic suspension allograft (ASA)
Description: Human amniotic suspension allograft (ASA) intra-articular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human amniotic suspension allograft (ASA)
Description: Human amniotic suspension allograft (ASA) intra-articular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human amniotic suspension allograft (ASA)
Description: Human amniotic suspension allograft (ASA) intra-articular injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Human amniotic suspension allograft (ASA)
Description: Human amniotic suspension allograft (ASA) intra-articular injection.
Study: NCT05319093

Intervention type: DRUG
Intervention: Ozanimod
Description: Three-months, longitudinal observational period

Intervention type: DRUG
Intervention: Ozanimod
Description: Three-months, longitudinal observational period
Study: NCT06331676

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tissue collection
Description: Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tissue collection
Description: Eutopic and ectopic endometrium biopsies, additional blood and peritoneal fluid sampling

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Data collection
Description: Questionnaire on menstrual health and history of hormone treatments for the research purpose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Data collection
Description: Questionnaire on menstrual health and history of hormone treatments for the research purpose
Study: NCT04528771

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNO
Description: Six-hour SNO treatment by inhalation at a sequential increasing dose regimen of 20 ppm x 2 hr, 40 ppm x 2 hr, 80 ppm x 2 hr. Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen gas
Description: Six-hour nitrogen gas treatment by inhalation.Patient care and follow-up during and after ENO administration will follow the critical care clinical SOPs developed by our institution (attached in Additional Information), which are consistent with the guidelines set out by the World Health Organization.
Study: NCT05263947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab and Icotinib
Description: Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle; Icotinib orally twice daily at 250mg/day
Study: NCT05245396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
Study: NCT06253676

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Problem Management Plus (PM+)
Description: Validated across multiple low- and middle-income country settings, PM+ is World Health Organization-developed, five-session task-sharing intervention for mild to moderate distress. Per the (manualized) intervention, trained non-specialist providers coach eligible clients to address practical problems and/or distress in their daily lives via the use of fundamental cognitive behavioral strategies (e.g., deep breathing and stress management, behavioral activation, strengthening of social support, etc.).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Problem Management Plus (PM+)
Description: Validated across multiple low- and middle-income country settings, PM+ is World Health Organization-developed, five-session task-sharing intervention for mild to moderate distress. Per the (manualized) intervention, trained non-specialist providers coach eligible clients to address practical problems and/or distress in their daily lives via the use of fundamental cognitive behavioral strategies (e.g., deep breathing and stress management, behavioral activation, strengthening of social support, etc.).
Study: NCT05869604

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEALTHY AYA
Description: 8-session health lifestyle behavior intervention combining behavioral symptom management strategies with strategies to improve diet and increase physical activity.

Intervention type: OTHER
Group type: OTHER
Intervention: Education Control
Description: Participants will receive paper materials on topics of relevance to adolescent and young adult cancer survivors.
Study: NCT04967274

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Startling acoustic stimulus
Description: StartReact: involuntary triggering of a planed movement by a loud acoustic stimulus.
Study: NCT05245396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ref (TF2)
Description: Participants will receive 2 single oral doses of Ref (TF2) on Day 1 in treatment period 1, 2, or 3 of Part A, B, C and D.
Study: NCT05485012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Double-blind administration of marijuana

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marijuana
Description: Double-blind administration of marijuana

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid
Description: Double-blind administration of an opioid agonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid
Description: Double-blind administration of an opioid agonist
Study: NCT04692493

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: targeted synthetic DMARD class
Description: Switching to a targeted synthetic DMARD (choice from targeted synthetic DMARDs; currently available are tofacitinib, baricitinib, upadacitinib) in people with active RA despite current treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-TNFi-biologic class
Description: Switching to a non-TNFi-biologic (choice from non-TNFi-biologics; currently available are rituximab, abatacept, tocilizumab, or sarilumab) in people with active RA despite current treatment,
Study: NCT05509257

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Participants will receive a single oral dose in randomized, crossover fashion with a 2 week wash out period between interventions. Medication will be taken 2 hours prior the neuroimaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
Study: NCT04470752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capsaicin 1% oral solution
Description: Capsaicin 1.0 micrograms/ml

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: InOrpha Solution
Description: glycerol based suspension vehicle
Study: NCT05834959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An Educational and Training Program
Description: Education and practical training program designed to evaluate the effects of training on movement confidence, low back dysfunction and changes in rates of lower back injury
Study: NCT06530628

Intervention type: BEHAVIORAL
Intervention: Adult patients resident in Pavillon C of the Pierre Garraud Hospital
Description: Adult patients resident in Pavillon C of the Pierre Garraud Hospital, aged over 70, polypathological, with or without undernutrition.~The intervention involves the diffusion of culinary odors using diffusers in the unit's hallways, 20 minutes before lunch, from Monday to Friday, for a period of three weeks.~This experiment will be repeated over 18 weeks (6 cycles), alternating meals without olfactory stimulation (cycles 1, 3 and 5) and meals with stimulation (cycles 2, 4 and 6).~The 3-week rhythm corresponds to the menu cycle proposed by the Unité Centrale de Production Alimentaire (UCPA). Thus, the menu will be the same whether or not it is associated with the diffusion of culinary scents.
Study: NCT06522854

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil 50 mg Oral Tablet
Description: Sildenafil 50 mg given orally every eight hours up to three times while mother is in labor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablet given orally every eight hours up to three times while mother is in labor
Study: NCT05463952

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vepdegestrant
Description: ARV-471 will be administered orally QD with food, in continuous dosing over 28-day cycles.
Study: NCT04877691

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medi-546
Description: Patients will have IP administered or will self-administer IP under supervision by site staff at Week 0 and Week 1 and, for patients participating in the OLE period, at Week 52. For weekly doses coinciding with subsequent on-site visits, patients will also have IP administered or will self-administer IP under supervision by site staff, and in addition will receive a set of kits (including back-up kits) for at-home administration.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for injection in aPFS
Study: NCT05577065

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: Single strain probiotic in the form of a sachet with a daily dose of 3E+9 Colony Forming Unit (CFU) per day for 26 weeks.
Study: NCT05078918

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive care program
Description: Comprehensive care program includes education and re-evaluation process. Education using video-materials to help patients adapt to the new normal before and after surgery. And re-evaluation patient's needs 1 month after surgery and arrangement resources.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care includes encouraging deep breathing and exercise using inspirometer, postoperative early ambulation, giving information at discharge and follow up 1 month after surgery.
Study: NCT05577065

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in the form of a sachet once daily for 26 weeks
Study: NCT06351761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Device (Withings SCT02) 30 second Electrocardiogram recording
Description: 30 second ECG recording with investigational device (Withings SCT02)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Device (Withings SCT02) 30 second Electrocardiogram recording
Description: 30 second ECG recording with investigational device (Withings SCT02)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording
Description: 30 second ECG recording with reference device (Schiller Cardiovit FT-1)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference Device (Schiller Cardiovit FT-1) 30 second Electrocardiogram recording
Description: 30 second ECG recording with reference device (Schiller Cardiovit FT-1)
Study: NCT05449132

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTX-GRT7039
Description: RTX-GRT7039 intra-articular injection.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching RTX-GRT7039 intra-articular injection.
Study: NCT06344923

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ileostomy with a support rod instead of the layer of peritoneum and anterior rectus sheath suturing
Description: The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. A support rod, made of a 24# silicone drainage tube with a 1ml syringe was passed through the mesentery of the small intestine. The support rod was removed two weeks after surgery. It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ileostomy with the layer of the peritoneum and anterior rectus sheath suturing
Description: The terminal ileum about 30cm proximal to the cecum was recognized and was lifted out of the body through the auxiliary incision at the right lower abdomen and made sure that the ileum was not twisted. Appropriate sutures can be used to narrow the peritoneal incision, preferably by inserting one finger. The seromuscular layer of the ileum or the mesentery was intermittently sutured with peritoneum and the anterior sheath of the rectus abdominis circumferentially with 8-10 stitches (3-0 silk thread). It is appropriate that the ileum wall protruded from the epidermis by about 3cm. After suturing trocar sites, the loop ileostomy was opened along the longitudinal axis of the intestinal wall, and 4-0 absorbable suture was used to fix the stoma and subcutaneous tissue circumferentially with 16-20 stitches
Study: NCT06578338

Intervention type: OTHER
Intervention: Physical height measurement
Description: Physical height will be measured and images will be collected for AI to estimate the height
Study: NCT04886037

Intervention type: OTHER
Intervention: sestrin
Description: Serum sestrin levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group.

Intervention type: OTHER
Intervention: sestrin
Description: Serum sestrin levels involved in inflammation and energy metabolism are compared between endometriosis and healthy control group.